Inhibitors of αvβ3 and αvβ5 integrins have previously been shown to inhibit tumor angiogenesis and growth and have entered human clinical trials. Andrew Reynolds and his coworkers now show that low (nanomolar) concentrations of these inhibitors can unexpectedly promote VEGF-dependent tumor angiogenesis and growth in vivo. Such effects could compromise the anticancer efficacy of these agents in humans.
- Andrew R Reynolds
- Ian R Hart
- Kairbaan M Hodivala-Dilke